These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

363 related articles for article (PubMed ID: 32366290)

  • 41. Mesenchymal stromal cells for acute respiratory distress syndrome (ARDS), sepsis, and COVID-19 infection: optimizing the therapeutic potential.
    Gorman E; Millar J; McAuley D; O'Kane C
    Expert Rev Respir Med; 2021 Mar; 15(3):301-324. PubMed ID: 33172313
    [No Abstract]   [Full Text] [Related]  

  • 42. The role of natriuretic peptide estimation in severe COVID-19.
    Mahajan K; Negi P
    Monaldi Arch Chest Dis; 2020 Apr; 90(2):. PubMed ID: 32340429
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Paracrine factors from mesenchymal stem cells: a proposed therapeutic tool for acute lung injury and acute respiratory distress syndrome.
    Li J; Huang S; Wu Y; Gu C; Gao D; Feng C; Wu X; Fu X
    Int Wound J; 2014 Apr; 11(2):114-21. PubMed ID: 24373614
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Mesenchymal stromal cells and their secreted extracellular vesicles as therapeutic tools for COVID-19 pneumonia?
    Muraca M; Pessina A; Pozzobon M; Dominici M; Galderisi U; Lazzari L; Parolini O; Lucarelli E; Perilongo G; Baraldi E
    J Control Release; 2020 Sep; 325():135-140. PubMed ID: 32622963
    [TBL] [Abstract][Full Text] [Related]  

  • 45. The Promise of Mesenchymal Stem Cells Therapy for Acute Respiratory Distress Syndrome Caused by COVID-19.
    Gu J; Zhao Q; Han Z; Han Z
    Curr Stem Cell Res Ther; 2021; 16(3):277-285. PubMed ID: 32729428
    [TBL] [Abstract][Full Text] [Related]  

  • 46. [Mesenchymal stem cells in therapy of coronavirus disease 2019 - a review].
    Shi X; Yu L; Ding C
    Sheng Wu Gong Cheng Xue Bao; 2020 Oct; 36(10):1979-1991. PubMed ID: 33169564
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Advances in the Regulation of Macrophage Polarization by Mesenchymal Stem Cells and Implications for ALI/ARDS Treatment.
    Liu C; Xiao K; Xie L
    Front Immunol; 2022; 13():928134. PubMed ID: 35880175
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Mesenchymal Stem Cell-Based Therapy as an Alternative to the Treatment of Acute Respiratory Distress Syndrome: Current Evidence and Future Perspectives.
    Fernández-Francos S; Eiro N; González-Galiano N; Vizoso FJ
    Int J Mol Sci; 2021 Jul; 22(15):. PubMed ID: 34360616
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [Mesenchymal stem cells in the treatment of COVID-19-progress and challenges].
    Wang J; Zou W; Liu J
    Sheng Wu Gong Cheng Xue Bao; 2020 Oct; 36(10):1970-1978. PubMed ID: 33169563
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Treatment of severe COVID-19 with human umbilical cord mesenchymal stem cells.
    Shu L; Niu C; Li R; Huang T; Wang Y; Huang M; Ji N; Zheng Y; Chen X; Shi L; Wu M; Deng K; Wei J; Wang X; Cao Y; Yan J; Feng G
    Stem Cell Res Ther; 2020 Aug; 11(1):361. PubMed ID: 32811531
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Host-directed therapies: a potential solution to combat COVID-19.
    Baindara P; Agrawal S; Mandal SM
    Expert Opin Biol Ther; 2020 Oct; 20(10):1117-1120. PubMed ID: 32783643
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Mesenchymal stem cell research progress for the treatment of COVID-19.
    Yao D; Ye H; Huo Z; Wu L; Wei S
    J Int Med Res; 2020 Sep; 48(9):300060520955063. PubMed ID: 32972277
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Extracorporeal membrane oxygenation for COVID-19-associated severe acute respiratory distress syndrome and risk of thrombosis.
    Beyls C; Huette P; Abou-Arab O; Berna P; Mahjoub Y
    Br J Anaesth; 2020 Aug; 125(2):e260-e262. PubMed ID: 32414510
    [No Abstract]   [Full Text] [Related]  

  • 54. Mesenchymal Stem Cell-Based Therapy for COVID-19: Possibility and Potential.
    Xiong J; Bao L; Qi H; Feng Z; Shi Y
    Curr Stem Cell Res Ther; 2021; 16(2):105-108. PubMed ID: 32479246
    [TBL] [Abstract][Full Text] [Related]  

  • 55. State of the Art Review of Cell Therapy in the Treatment of Lung Disease, and the Potential for Aerosol Delivery.
    Brave H; MacLoughlin R
    Int J Mol Sci; 2020 Sep; 21(17):. PubMed ID: 32899381
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Assessment of pulmonary surfactant in COVID-19 patients.
    Schousboe P; Wiese L; Heiring C; Verder H; Poorisrisak P; Verder P; Nielsen HB
    Crit Care; 2020 Sep; 24(1):552. PubMed ID: 32894160
    [No Abstract]   [Full Text] [Related]  

  • 57. Review of Trials Currently Testing Stem Cells for Treatment of Respiratory Diseases: Facts Known to Date and Possible Applications to COVID-19.
    Majolo F; da Silva GL; Vieira L; Timmers LFSM; Laufer S; Goettert MI
    Stem Cell Rev Rep; 2021 Feb; 17(1):44-55. PubMed ID: 32827081
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Spontaneous hemothorax in 4 COVID-19 ARDS patients on VV-ECMO revealing pulmonary artery aneurysms.
    Desnos C; Boussouar S; Hekimian G; Redheuil A; Combes A
    Crit Care; 2020 Nov; 24(1):638. PubMed ID: 33158462
    [No Abstract]   [Full Text] [Related]  

  • 59. The ARDSnet protocol may be detrimental in COVID-19.
    Tsolaki V; Zakynthinos GE; Makris D
    Crit Care; 2020 Jun; 24(1):351. PubMed ID: 32546230
    [No Abstract]   [Full Text] [Related]  

  • 60. Mesenchymal Stem Cells: A New Piece in the Puzzle of COVID-19 Treatment.
    Saldanha-Araujo F; Melgaço Garcez E; Silva-Carvalho AE; Carvalho JL
    Front Immunol; 2020; 11():1563. PubMed ID: 32719683
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.